Long non-coding RNA TUG1 regulates multiple glycolytic enzymes in hepatocellular carcinoma cells by sponging microRNA-122-5p

Abstract

Hepatocellular carcinoma (HCC) remains the third leading cause of cancer-related deaths worldwide; however, its therapeutic options are limited. Understanding the molecular mechanisms of HCC could provide insight into new therapies. Emerging studies indicate the important role of long-noncoding RNAs (lncRNAs) in the pathogenesis of HCC. The expression of the well-studied lncRNA taurine upregulated gene 1 (TUG1) is upregulated in HCC tissues, but its transcriptomic effects in HCC cells remain unexplored. We established TUG1-knockdown and control HCC cells for RNA-seq experiments. KEGG analysis revealed glycolysis as the top enriched pathway upon TUG1 silencing. Accordingly, TUG1-depleted HCC cells showed impairments in glucose uptake, ATP synthesis, and lactate production. Clinical HCC tissue data revealed positive gene expression correlations between TUG1 and several glycolysis-related genes. To identify a molecular function of TUG1 in glycolysis, we explored the competing endogenous model and used bioinformatic tools to find the five microRNAs (miRNAs) that had the most binding sites for TUG1. Among these miRNAs, miR-122-5p exhibited an inverse correlation in gene expression with most TUG1-regulated glycolysis genes, including PKM, ALDOA, ENO2, and PFKM. Dual-luciferase assays demonstrated the direct interaction between TUG1 and miR-122-5p and between miR-122-5p and the 3ʹ untranslated regions of both PKM and ALDOA. We further showed that inhibition of miR-122-5p alleviated the suppression of glycolysis induced by TUG1 depletion. Together, our RNA-seq analysis of TUG1-depleted HCC cells, combined with clinical data, reveals a critical role of TUG1 in regulating glycolysis and provides new insight into its oncogenic function in HCC.

Keywords

hepatocellular carcinoma / TUG1 / long-noncoding RNA / microRNA / glycolysis

Fundings

This work was financially supported by the Thailand Science Research and Innovation Fund Chulalongkorn University (Grant No. HEAF67300078), the 90th Anniversary Scholarship, Chulalongkorn University Ratchadapisek Sompoch Fund (Grant No. Batch #55, T. Boonto), and the Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University. T. Boonto was supported by the scholarship from the Graduate School, Chulalongkorn University, to commemorate the 72nd anniversary of His Majesty King Bhumibol Adulyadej (Grant No. Batch #22).

Acknowledgments

We would like to thank all members of the Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, for their technical assistance with experiments.

References

[1] Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. doi: 10.1056/NEJMra1713263

[2] Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: Special focus on fatty liver disease[J]. Front Oncol, 2020, 10: 601710. doi: 10.3389/fonc.2020.601710

[3] Chen S, Cao Q, Wen W, et al. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities[J]. Cancer Lett, 2019, 460: 1-9. doi: 10.1016/j.canlet.2019.114428

[4] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606. doi: 10.1016/j.jhep.2022.08.021

[5] The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome[J]. Nature, 2012, 489(7414): 57-74. doi: 10.1038/nature11247

[6] Taniue K, Akimitsu N. The functions and unique features of LncRNAs in cancer development and tumorigenesis[J]. Int J Mol Sci, 2021, 22(2): 632. doi: 10.3390/ijms22020632

[7] Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: Definitions, functions, challenges and recommendations[J]. Nat Rev Mol Cell Biol, 2023, 24(6): 430-447. doi: 10.1038/s41580-022-00566-8

[8] Liu S, Dang H, Lim DA, et al. Long noncoding RNAs in cancer metastasis[J]. Nat Rev Cancer, 2021, 21(7): 446-460. doi: 10.1038/s41568-021-00353-1

[9] Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells[J]. Oncol Lett, 2019, 18(5): 4393-4402.

[10] Lin Y, Wu M, Huang Y, et al. Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 188-203. doi: 10.1002/hep.29462

[11] Farzaneh M, Ghasemian M, Ghaedrahmati F, et al. Functional roles of lncRNA-TUG1 in hepatocellular carcinoma[J]. Life Sci, 2022, 308: 120974. doi: 10.1016/j.lfs.2022.120974

[12] Fan Z, Pan H, Qu N, et al. LncRNA taurine upregulated gene 1 in liver disease[J]. Clin Chim Acta, 2024, 560: 119752. doi: 10.1016/j.cca.2024.119752

[13] Ariyachet C, Chuaypen N, Kaewsapsak P, et al. MicroRNA-223 suppresses human hepatic stellate cell activation partly via regulating the actin cytoskeleton and alleviates fibrosis in organoid models of liver injury[J]. Int J Mol Sci, 2022, 23(16): 9380. doi: 10.3390/ijms23169380

[14] Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1): 126. doi: 10.1186/s13046-020-01629-4

[15] Li J, Zhang M, An G, et al. LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis[J]. Exp Biol Med, 2016, 241(6): 644-649. doi: 10.1177/1535370215622708

[16] Cao Y, Chai W, Wang Y, et al. lncRNA TUG1 inhibits the cancer stem cell-like properties of temozolomide-resistant glioma cells by interacting with EZH2[J]. Mol Med Rep, 2021, 24(1): 533. doi: 10.3892/mmr.2021.12172

[17] Yang X, Sun L, Wang L, et al. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4[J]. Biomed Pharmacother, 2019, 118: 109386. doi: 10.1016/j.biopha.2019.109386

[18] Yang X, Yao B, Niu Y, et al. Hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122-5p/CTNND2 axis[J]. Biochem Biophys Res Commun, 2019, 518(2): 239-245. doi: 10.1016/j.bbrc.2019.08.039

[19] Wei X, Liu H, Li X, et al. Over-expression of MiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4[J]. Ann Hepatol, 2019, 18(6): 869-878. doi: 10.1016/j.aohep.2019.07.005

[20] Huang H, Zhu Y, Li S. MicroRNA-122 mimic transfection contributes to apoptosis in HepG2 cells[J]. Mol Med Rep, 2015, 12(5): 6918-6924. doi: 10.3892/mmr.2015.4254

[21] Yin S, Fan Y, Zhang H, et al. Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis[J]. Nat Commun, 2016, 7: 11012. doi: 10.1038/ncomms11012

[22] Lashkarian MF, Hashemipour N, Niaraki N, et al. MicroRNA-122 in human cancers: From mechanistic to clinical perspectives[J]. Cancer Cell Int, 2023, 23(1): 29. doi: 10.1186/s12935-023-02868-z

[23] Wang Z, Qin C, Zhang J, et al. MiR-122 promotes renal cancer cell proliferation by targeting Sprouty2[J]. Tumour Biol, 2017, 39(2): 1010428317691184. doi: 10.1177/1010428317691184

[24] Lu L, Huang J, Mo J, et al. Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration, invasion, and glycolysis by regulating the miR-524-5p/SIX1 axis[J]. Cell Mol Biol Lett, 2022, 27(1): 17. doi: 10.1186/s11658-022-00309-9

[25] Jiang Z, Wang X, Li J, et al. Aldolase A as a prognostic factor and mediator of progression via inducing epithelial-mesenchymal transition in gastric cancer[J]. J Cell Mol Med, 2018, 22(9): 4377-4386. doi: 10.1111/jcmm.13732

[26] Feng J, Wu L, Ji J, et al. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 204. doi: 10.1186/s13046-019-1194-z

[27] Sobanski T, Suraweera A, Burgess JT, et al. The fructose-bisphosphate, Aldolase A (ALDOA), facilitates DNA-PKcs and ATM kinase activity to regulate DNA double-strand break repair[J]. Sci Rep, 2023, 13(1): 15171. doi: 10.1038/s41598-023-41133-1

[28] Steták A, Veress R, Ovádi J, et al. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death[J]. Cancer Res, 2007, 67(4): 1602-1608. doi: 10.1158/0008-5472.CAN-06-2870

[29] Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: From cells to clinic[J]. Trends Genet, 2022, 38(6): 613-626. doi: 10.1016/j.tig.2022.02.006

[30] Chelakkot C, Chelakkot VS, Shin Y, et al. Modulating glycolysis to improve cancer therapy[J]. Int J Mol Sci, 2023, 24(3): 2606. doi: 10.3390/ijms24032606

[31] Wang Q, Liu J, Chen Z, et al. Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: A comprehensive review[J]. Biomed Pharmacother, 2024, 170: 116021. doi: 10.1016/j.biopha.2023.116021

[32] Statello L, Guo CJ, Chen LL, et al. Gene regulation by long non-coding RNAs and its biological functions[J]. Nat Rev Mol Cell Biol, 2021, 22(2): 96-118. doi: 10.1038/s41580-020-00315-9

[33] Yacoub NA, Romanowska M, Haritonova N, et al. Optimized production and concentration of lentiviral vectors containing large inserts[J]. J Gene Med, 2007, 9(7): 579-584. doi: 10.1002/jgm.1052

[34] Kreiss P. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency[J]. Nucleic Acids Res, 1999, 27(19): 3792-3798. doi: 10.1093/nar/27.19.3792

[35] Salehi S, Taheri MN, Azarpira N, et al. State of the art technologies to explore long non-coding RNAs in cancer[J]. J Cell Mol Med, 2017, 21(12): 3120-3140. doi: 10.1111/jcmm.13238